Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
- 作者: Knyazev O1, Kagramanova A1, Lishchinskaya A1, Samsonova N1, Orlova N1, Rogozina V1, Parfenov A1
-
隶属关系:
- A.S. Loginov Moscow Clinical Research Center, Moscow Healthcare Department
- 期: 卷 90, 编号 6 (2018)
- 页面: 74-80
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32784
- DOI: https://doi.org/10.26442/terarkh201890674-80
- ID: 32784
如何引用文章
全文:
详细
作者简介
O Knyazev
A.S. Loginov Moscow Clinical Research Center, Moscow Healthcare Departmentд.м.н., зав. отд-нием воспалительных заболеваний кишечника Moscow, Russia
A Kagramanova
A.S. Loginov Moscow Clinical Research Center, Moscow Healthcare Departmentк.м.н., с.н.с. отд-ния патологии кишечника Moscow, Russia
A Lishchinskaya
A.S. Loginov Moscow Clinical Research Center, Moscow Healthcare Departmentк.м.н., с.н.с. отд-ния воспалительных заболеваний кишечника Moscow, Russia
N Samsonova
A.S. Loginov Moscow Clinical Research Center, Moscow Healthcare Departmentк.м.н., зав. отд-нием УЗИ диагностики Moscow, Russia
N Orlova
A.S. Loginov Moscow Clinical Research Center, Moscow Healthcare Departmentзав. отд-нием рентгенологии Moscow, Russia
V Rogozina
A.S. Loginov Moscow Clinical Research Center, Moscow Healthcare Departmentк.м.н., врач-эндоскопист отд-ния внутрипросветной эндоскопии Moscow, Russia
A Parfenov
A.S. Loginov Moscow Clinical Research Center, Moscow Healthcare Department
Email: asfold@mail.ru
д.м.н., проф., зав. отд. патологии кишечника Moscow, Russia
参考
- Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л., Белоусова Е.А., Шифрин О.С., Абдулганиева Д.И., Абдулхаков Р.А., Алексеева О.П., Алексеенко С.А., Ачкасов С.И., Барановский А.Ю., Болихов К.В., Валуйских Е.Ю., Варданян А.В., Веселов А.В., Веселов В.В., Головенко А.О., Головенко О.В., Григорьев Е.Г., Губонина И.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации колопроктологов России по диагностике и лечению болезни Крона. Колопроктология. 2017;2(60):7-29.
- Steinhart A.H, Ewe K, Griffiths A.M, Modigliani R, Thomsen O.O. Corticosteroids for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2003;(4):CD000301.
- Sartor R.B, Hoentjen F. Proinflammatory cytokines and signaling pathways in intestinal innate immune cells. Mucos Immunol. 2005;30:681-701. doi: 10.1016/B978-012491543-5/50039-5
- Sipponen T, Nuutinen H, Turunen U, Färkkilä M. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis. 2010 Dec;16(12):2131-6. doi: 10.1002/ibd.21300
- Князев О.В, Каграманова А.В, Ручкина И.Н, Фадеева Н.А, Лищинская А.А, Болдырева О.Н, Жулина Е.Ю, Щербаков П.Л, Орлова Н.В, Кирова М.В, Парфенов А.И. Эффективность адалимумаба при болезни Крона в реальной клинической практике. Терапевтический архив. 2017;89(2):20-7.
- Rubin D.T, Kane S, Jaganathan S, Palmer L, Anissa Cyhaniuk A. Web Exclusive: Real-World Anti-TNF Dose Escalation in Patients With Crohn's Disease. Am J Pharm Benefits. 2015;7(5):e135-e140.
- De Silva P.S.A, Nguyen D.D, Sauk J, Korzenik J, Yajnik V, Ananthakrishnan A.N. Long - term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther. 2012 Sep;36(5):459-66. doi: 10.1111/j.1365-2036.2012.05214.x
- Han P.D, Cohen R.D. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs. 2004;64:1766-7. doi: 10.2165/00003495-200464160-00004
- Reich K, Ortonne J.P, Gottlieb A.B, Terpstra I.J, Coteur G, Tasset C, Mease P. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo - controlled trial with a re - treatment extension. Br J Dermatol. 2012;167(1):180-90. doi: 10.1111/j.1365-2133.2012.10941.x
- Harrold L.R, Litman H.J, Saunders K.C, Dandreo K.J, Gershenson B, Greenberg J.D, Low R, Stark J, Suruki R, Jaganathan S, Kremer J.M, Yassine M. One - year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real - world setting: data from a national U.S. rheumatoid arthritis registry. Arthritis Res Ther. 2018 Jan 2;20(1):2. doi: 10.1186/s13075-017-1496-5
- Vande Casteele N, Feagan B.G, Vermeire S, Yassine M, Coarse J, Kosutic G, Sandborn W.J. Exposure - response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease. Aliment Pharmacol Ther. 2018 Jan;47(2):229-37. doi: 10.1111/apt.14421
- Vavricka S.R, Spasojevic M, Rogler G, Schoepfer A.M, Seibold F, Borovicka J, Frei P, Zeitz J, Greuter T, Manser C, Scharl M, Misselwitz B, Straumann A, Michetti P, Biedermann L; Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. Dig Dis. 2017;35(5):423-32. doi: 10.1159/000475494
- Sandborn W.J, Wolf D.C, Kosutic G, Parker G, Schreiber S, Lee S.D, Abraham B, Afzali A, Arsenescu R.I, Gutierrez A, Spearman M, Coarse J, Feagan B.G. Effects of Transient and Persistent Anti - drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. Inflamm Bowel Dis. 2017 Jul;23(7):1047-56. doi: 10.1097/MIB.0000000000001100
- Sandborn W.J, Schreiber S, Hanauer S.B, et al. Reinduction with Certolizumab Pegol in Patients with Relapsed Crohn’s Disease: Results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010;8:696-702. doi: 10.1016/j.cgh.2010.03.024
- Lichtenstein G.R. Continuous Therapy with Certolizumab Pegol Maintains Remission of Patients with Crohn’s Disease for up to 18 Months. Clin Gastroenterol Hepatol. 2010;8:600-9. doi: 10.1016/j.cgh. 2010.01.014